Semaglutide Plus Luseogliflozin for MASH

On August 17, 2026, Diabetes, Obesity and Metabolism published a randomised, open-label trial by Miyake, Yoshida, and colleagues testing whether adding the SGLT2 inhibitor luseogliflozin to semaglutide improves liver histology in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes^[1]. Over 52 weeks, the combination did not clear the trial's pre-specified statistical bar for the main histological endpoints, even though every measured outcome numerically favoured the two-drug combination over semaglutide alone.

That mixed result is a useful case study in reading a small trial correctly: numbers moving in the right direction are not the same thing as a proven benefit, and this article walks through what the study found, what it did not establish, and how it sits alongside the much larger semaglutide MASH trial that already changed prescribing.

What the trial tested

Sixty adults with biopsy-confirmed MASH and type 2 diabetes were randomised in Japan to either semaglutide plus luseogliflozin (24 participants) or semaglutide alone (36 participants) for 52 weeks^[1]. Luseogliflozin is an SGLT2 inhibitor, a class of drug that lowers blood glucose by blocking glucose reabsorption in the kidney. It received its first global regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency in 2014 for type 2 diabetes, sold under the brand Lusefi^[3]. It does not carry an FDA or EMA approval, and it has no approved indication for MASH anywhere. The trial paired it with an established GLP-1 receptor agonist to see whether combining two different metabolic mechanisms would do more for the liver than the GLP-1 agonist on its own.

The trial was open-label, meaning participants and clinicians knew which arm they were in, which is a weaker design than the placebo-controlled, double-blind structure used in large regulatory trials. All participants had liver biopsies at baseline and at week 52, the reference-standard method for assessing MASH severity and fibrosis stage.

What the results actually showed

MASH resolution without worsening of fibrosis occurred in 34.9% of the combination group versus 19.4% of the monotherapy group^[1]. A NAFLD activity score improvement of at least one point was seen in 75.5% versus 55.6%. Fibrosis improvement of at least one stage occurred in 26.9% versus 13.9%. In the trial's primary, full-analysis-set comparison, none of these differences reached statistical significance. In a secondary, per-protocol analysis restricted to participants who completed the trial as designed, the NAFLD activity score result reached what the authors describe as nominal significance, a term that flags a result crossing the p<0.05 threshold in an analysis that was not the trial's primary, pre-registered comparison.

Outside the liver-biopsy endpoints, the combination group did show clearer secondary benefits: greater reductions in body weight, blood glucose control, liver enzymes (aminotransferases), and liver stiffness measured by elastography, compared with semaglutide alone^[1]. The authors reported no new safety signals for the combination beyond the adverse-event profile already known for each drug individually.

Why a trial can show a trend without proving a benefit

With only 60 participants split across two unevenly sized arms, this trial was not statistically powered to detect a moderate difference in histological endpoints between groups. That is the most direct explanation for why numbers that all point the same direction still failed to clear the significance bar in the primary analysis: the sample was simply too small to distinguish a real effect from chance variation with confidence.

This is a common and honest outcome in early-phase and exploratory trials, and it is different from a trial that shows no effect at all. The distinction matters for how readers should treat the result: as a signal worth following up in a larger, adequately powered trial, not as evidence that the combination works.

How this fits with the existing semaglutide-MASH evidence

Semaglutide's own MASH evidence base is considerably larger. The Phase 3 ESSENCE trial randomised 1,197 patients 2:1 to semaglutide or placebo, and its week-72 interim analysis reported steatohepatitis resolution without fibrosis worsening in 62.9% of the semaglutide group versus 34.3% on placebo, and fibrosis improvement without steatohepatitis worsening in 36.8% versus 22.4%, both statistically significant at P<0.001^[2]. That trial, roughly twenty times larger than the luseogliflozin add-on study, is the evidence base regulators relied on for semaglutide's MASH indication. The Miyake et al. trial does not change that picture. It asks a narrower, additive question: does stacking a second metabolic drug on top of semaglutide add more benefit, and on the histology endpoints specifically, the answer from this trial is not yet.

It is also worth separating the two drugs in regulatory terms. Semaglutide is an approved prescription medicine across the EU, UK and US for its labelled indications. Luseogliflozin's only approval is in Japan for type 2 diabetes, not for MASH, and not in the US or EU at all. Nothing in this trial changes either drug's approval status or extends an indication.

Why this matters

SGLT2 inhibitors and GLP-1 receptor agonists are two of the most-prescribed metabolic drug classes worldwide, and clinicians already combine them routinely for glycaemic control in type 2 diabetes. Whether combining them adds a meaningful liver benefit on top of semaglutide alone, for patients who specifically have MASH, is a genuinely open question this trial narrows without closing. A larger, adequately powered, ideally blinded trial would be needed before the combination could be treated as an evidence-backed liver strategy rather than a promising early signal. Readers tracking semaglutide research should watch for that follow-up trial rather than reading this one as a settled result.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide is a prescription medicine in every jurisdiction where it is approved, and any decision to combine it with another medicine belongs with a treating clinician who knows the patient's full history. PeptideMethods.com does not sell, distribute, or facilitate the sale of any product.